Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib with cytarabine versus imatinib alone in first chronic phase CML
2005-003839-41Phase 3Completed
- Sponsor
- HOVON
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by HOVON. Primary endpoint: Rate of major molecular response at 12 months. Started Jun 2007; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-003839-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003839-41.